You are here
- Home
All Discontinued Products
- collapse A randomised single centre phase I study to investigate the safety, tolerability and pharmacokinetics of oral multiple ascending daily doses of AZD1236 tablet by a single-blind, placebo-controlled, and single dose relative bioavailability of the oral suspension and oral tablet formulations by an open cross-over in healthy Japanese men
- collapse A Single-centre, Double-blind, Double-dummy, Randomised, Placebo-controlled, Four-period Crossover Study to Assess the Effect of Single Oral Doses of AZD5672 (600 mg and 150 mg) on QT/QTc Interval, Compared to Placebo, using Moxifloxacin (Avelox) as a Positive Control, in Healthy Male Volunteers
- collapse A Phase I, Open-Label, Dose-Escalation Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD7762 Administered as a Single Intravenous Agent and in Combination with Weekly Standard Dose Gemcitabine in Japanese Patients with Advanced Solid Malignan
- collapse A Phase I Open-label, Multi-center, Dose-escalation and Safety Expansion Study to Assess Safety, Tolerability, and Pharmacokinectics of AZD7762 Administered as a Single Intravenous Agent and in Combination With Weekly Standard Dose of Irinotecan in Patients With Advanced Solid Malignancies.
- collapse A Phase I, Single centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Oral Doses of AZD8075 in Healthy Male Volunteers
- collapse An Open-Label. Phase I Study to Assess the Excretion of Radioactivity, Metabolic Profiles and Pharmacokinetics folloiwing a Single Oral Dose of 60 mg of [14C] AZD1236 in Healthy Male Subjects
- collapse A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase II study to Assess the Efficacy of 28 Day Oral Administration of AZD1236 in Adult Patients with Cystic Fibrosis
- collapse A 16-Week Randomized, Double-blind, Parallel-group, Multicenter, Placebo- and Active- (Metformin) Controlled Study to Evaluate the Effect on Whole Body Insulin Sensitivity of Tesaglitazar Therapy when Administered to Patients with Type 2 Diabetes
- collapse An Open-Label, Multi-Center, Long-Term Extension Study to Evaluate the Safety and Tolerability of Oral Tesaglitazar 0.5mg When Added to Insulin Therapy in Patients with Type 2 Diabetes Mellitus (GALLEX 9)
- collapse The EXTEND Study: A Randomized, Double-Blind, Parallel-Group, Phase III b, Multi-Centre Study Evaluating Extended Prophylactic Treatment With Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events in Patients Undergoing Elective Hip Replacement or Hip Fracture Surgery.
